Cardinal Health, Inc. (CAH) Stock Analysis
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
Cardinal Health (CAH) appears undervalued based on its DCF valuation, offering a compelling investment opportunity within the stable healthcare distribution sector.
Investment Recommendation
Buy
Fair Value: $125.50
Current Price: $101.87
Upside/Downside: +23.2%
Based on a DCF analysis that projects steady free cash flow growth, Cardinal Health's implied fair value per share is higher than its current market price. This suggests the stock is undervalued, offering an attractive entry point for investors seeking exposure to a defensive sector with a solid track record.
Key Metrics
- Market Cap: $27.1B
- P/E Ratio: 18.1x
- Forward P/E: 12.4x
- Revenue Growth (YoY): 9.3%
- Net Margin: 1.1%
- ROE: 31.7%
- Debt/Equity: 0.76
- Dividend Yield: 1.12%
Strengths
- Dominant market position in pharmaceutical distribution, handling a significant portion of U.S. prescription drugs.
- Strong revenue growth, with a 9.3% increase year-over-year in the most recent reported period.
- Diversified business model with exposure to both pharmaceutical and medical product distribution.
- Strategic investments in technology and supply chain efficiency to enhance customer service and reduce costs.
Risk Factors
- Dependence on a few large pharmaceutical manufacturers for a significant portion of its revenue.
- Potential for increased competition from other distributors and the growth of alternative distribution channels.
- Regulatory scrutiny and potential changes in healthcare policies that could impact reimbursement and drug pricing.
- Exposure to litigation risks inherent in the healthcare industry.